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Objective: To investigate the anxiolytic properties of a standardized extract of
Sceletium tortuosum (trademarked―Zembrin®).
Methods: Two studies utilized a placebo‐controlled, double‐blind, between‐subject
experimental design to investigate the effects of a single dose of Sceletium tortuosum
(25 mg, Zembrin®) on laboratory stress/anxiety responding in 20 young healthy
volunteers. To elicit feelings of stress/anxiety, participants completed 20 min of the
multitasking framework in study1anda5‐min simulatedpublic speaking task in study2.
Study 1 measured subjective experiences of mood at baseline, prestress induction,
and poststress induction. Study 2 measured subjective experiences of anxiety and
physiological indicators of stress (heart rate [HR] and galvanic skin response) at
baseline, prestress induction, during stress induction, and poststress induction.
Results: A series of analysis of covariances (baseline entered as the covariate)
revealed no treatment effect in study 1; however, study 2 revealed subjective
anxiety levels to be significantly lower in the Zembrin® group at the prestress
induction point and a significant interaction between treatment and time on HR.
Taken together, results indicate that a single dose of Zembrin® can ameliorate
laboratory stress/anxiety responding in healthy volunteers.
Conclusion: We provide the first tentative behavioral evidence to support the
anxiolytic properties of Sceletium tortuosum (25 mg Zembrin®).
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1 | INTRODUCTION
Sceletium tortuosum (L.) N.E.Br. (Mesembryanthemaceae) is used by
some tribal people of South Africa to reduce feelings of pain and hun-
ger, ameliorate stress, and enhance mental and physical performance
(see review by Gericke & Viljoen, 2008). In western cultures, the pur-
ported therapeutic properties of Sceletium tortuosum have received
limited scientific scrutiny; however, early research is promising. For
example, Smith (2011) reported evidence of the anxiolytic properties
of a low dose (5 mg/kg/day) but not a higher dose (20 mg/kg/day) of
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Sceletium tortuosum on restraint‐induced anxiety in rats.1 Similarly,
Hirabayashi, Ichikawa, Yoshi, Uchino, and Shimada (2004) demon-
strated reduced stress and anxiety in cats administered 10mg/kg/day.
More recently, a standardized extract of Sceletium tortuosum (trade-
marked as Zembrin®2) has accumulated a small body of evidence to
support its safety, cognitive enhancing, anxiolytic properties, and
identified potential biological mechanisms of action. With regards to
safety, Nell, Siebert, Chellan, and Gericke (2013) demonstrated that
both a low (8mg) and a higher (25mg) daily dose of Zembrin® ingested
for 3 months were well tolerated in healthy participants. With regards
to cognitive functioning, Dimpfel, Schombert, and Gericke (2016)
demonstrated a dose‐dependent attenuation of spectral power
following three acute doses of Zembrin® (2.5, 5.0, and 10.0 mg/kg) to
adult Fischer rats, and Chiu et al. (2014) demonstrated, in older human
adults, improved cognitive set flexibility and executive function
following 3 weeks of daily consumption (25 mg Zembrin® per day).
With regard to the anxiolytic effect of Zembrin®, two studies have
identified potential biological mechanisms of action, the first demon-
stratedZembrin® tobeadual serotonin (5‐HT) transporterblockerand
selective inhibitor of phosphodiesterase‐4 (Harvey, Young, Viljoen, &
Gericke, 2011) and the second demonstrated a single 25 mg dose of
Zembrin® could reduce anxiety‐related amygdala reactivity and
attenuated amygdala–hypothalamus coupling in healthy young vol-
unteers 2 h postdose (Terburg et al., 2013). To the authors' knowledge,
the anxiolytic effects of Zembrin® are yet to be investigated in a
behavioral study; therefore, we report for the first time the results of
two behavioral studies that directly tested the anxiolytic properties of
Zembrin®. The first study also investigated two additional purported
properties―the effects on feelings of hunger and memory perfor-
mance. We predict that Zembrin® will ameliorate stress/anxiety
responding to acute laboratory stressors in healthy volunteers.
2 | METHODS
2.1 | Design
Both studies utilized a placebo‐controlled, double‐blind, between‐
subject experimental design to investigate the anxiolytic effects of a
single dose of Zembrin® (25 mg) in healthy volunteers. Study 1
measured at baseline, prestress, and poststress induction. Study 2
measuredatbaseline,prestress,duringstress,andpoststress induction.
2.2 | Participants
Study 1: Twenty (six male) healthy volunteers (mean age 19.6 years;
SD 1.09; body mass index 20.87). Study 2: Twenty (11 male) healthy
volunteers (mean age 21.3 years; SD 1.38).
2.3 | Stress induction
2.3.1 | Study 1: Multitasking framework
The multi‐tasking framework (MTF; Purple Research Solutions) is a
computerized stressor that reliably elicits cognitive demand, negative
affect, stress, and anxiety (Scholey et al., 2009; Wetherell & Carter,
2014). The MTF requires participants to attend to four tasks simul-
taneously that vary in terms of time pressure and/or difficulty; tasks
are performance‐driven and demand is manipulated through
instructing participants to achieve as high a score as they can. The
current version consisted of four tasks (visual warning, mail alert,
telephone entry, and maths), which required visual monitoring,
accurate data entry, and mental arithmetic (for a detailed description
of tasks, see Wetherell & Carter, 2014).
2.3.2 | Study 2: Simulated public speaking task
On the day of testing, participants were informed that they would
be completing a 5‐min public speech to outline why they would be
the most suitable applicant for a job of their choosing. Following a
2‐min preparation period, participants stood in front of the
researcher and performed their speech, the researcher gave no
feedback, and participants were required to continue speaking for
the duration of the task. Participants were also informed that their
speech would be recorded and their performance considered by a
panel of experts.
2.4 | Outcome variables
2.4.1 | Study 1
Perceived Stress Scale (PSS; Cohen & Williamson, 1988): The PSS
was used to measure perceptions of stress during the previous
month. A higher score represents higher feelings of stress.
Bond–Lader Visual Analogue Scales (Bond & Lader, 1974): A
16‐item scale provides three mood dimensions as follows: (1) alert,
(2) calm, and (3) content. The Bond–Lader was utilized to confirm
stress induction and to assess any impact of treatment (scale uti-
lized in study 2 too).
Visual Analogue Hunger Scale: A 100‐mm line anchored by “not
hungry” to “very hungry.” Participants crossed the line at the point
that best described their current feeling. A score of 0 (not hungry) to
a score of 100 (very hungry). If results reveal a treatment effect on
hunger, hunger will be included as a covariate.
Immediate word recall: Two sets of 20 concrete nouns were
created giving an A–B or B–A order. Each list was presented for 60 s,
and participants were given 60 s for recall.
The National Aeronautics and Space Administration task load
index (NASA‐TLX; Hart & Staveland, 1988): The NASA‐TLX measures
six workload domains. Three of which reflect the respondents
perceived demands of the task (mental demand, physical demand,
1However, numerous side effects were also reported for both doses.
2The hydroethanolic extract of a select variety of Sceletium tortuosum plant standardized to
contain 0.35%–0.45% total alkaloids: mesembrenone and mesembrenol ≥60%, and
mesembrine <20%, HGH Inc.
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and temporal demand), and three reflect the interaction between the
task and the respondent (effort, perceived performance, and
frustration).
2.4.2 | Study 2
State–Trait Anxiety Inventory (STAI; Spielberger, 2010): A 40‐item
inventory split into two 20‐item sections. The first focuses on state
anxiety whereas the second focuses upon trait anxiety.
Visual Analogue Anxiety (VAa) Mood Scale (Wetherell, Craw,
Smith, & Smith, 2017): A 10‐point scale anchored by “not at all” to
“very anxious.” Participants marked the point that best describes
their current feeling. A score of 0 (not at all feeling anxious) to a
score of 10 (feeling very anxious).
Biopac (Biopac Systems, Inc, Unit MP35): Heart rate (HR) and
galvanic skin response (GSR) were utilized as physiological indicators
of anxiety.
2.5 | Procedure
All participants provided written informed consent and attended
between 8:30 a.m. and 10 a.m. Participants confirmed they had not
consumed food or drink (water being an exception) since 8 p.m. and
were randomly allocated placebo or Zembrin® treatment condition.
Ethical approval was granted from the Department of Psychology at
Northumbria University for study 1 and from the School of Social
Science, Business and Law at Teesside University for study 2. Par-
ticipants completed task order as detailed in Figure 1.
2.6 | Statistical analysis
To confirm the absence of any group difference in “background”
levels of stress/anxiety, baseline scores from the PSS (study 1) and
STAI (study 2) were analyzed by one‐way between group analysis of
variance (ANOVA).
2.6.1 | Study 1
Placebo data for the Bond–Lader was analyzed by one‐way repeated
measures ANOVA to confirm stress induction. To explore treatment
effects, each outcome measure was subject to an analysis of
covariance (ANCOVA; baseline score was entered as the covariate).
One‐way ANOVA was utilized for each domain of the NASA‐TLX (see
Table 1 for means and SE).
F I GUR E 1 Study protocol for study 1 and
study 2. Dosage ¼ 25 mg Sceletium tortuosum
(trademarked Zembrin®) or placebo. BL,
Bond–Lader Visual Analogue Mood Scale; IWR,
immediate word recall; PSS, Perceived Stress
Scale; STAI(s), State–Trait Anxiety Inventory
(state score); STAI (t), State–Trait Anxiety
Inventory (trait score); TLX, the National
Aeronautics and Space Administration task load
index; VAa, Visual Analogue Anxiety Scale; VAh,
Visual Analogue Hunger Scale
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2.6.2 | Study 2
Placebo data for the STAI(s), VAa scale, HR, and GSR were analyzed
by one‐way repeated measures ANOVA to confirm stress induction.
To explore treatment effects, each outcome was subject to ANCOVA
(baseline score was entered as the covariate) (See Table 2 for means
and SE).
3 | RESULTS
3.1 | Study 1
3.1.1 | Background stress
PSS: No significant difference between placebo and Zembrin® group
(F(1,18) ¼ 0.76, p ¼ 0.785).
3.1.2 | Stress induction
Amain effect of time on feelings of alertness (F(1,18)¼5.74, p¼0.012)
and calmness (F(1,18) ¼ 9.87, p ¼ 0.001) confirm stress induction.
3.1.3 | Effect of treatment
No treatment effects observed on any outcome measure.
3.2 | Study 2
3.2.1 | Background anxiety
STAI (trait): No difference between placebo and Zembrin® group
(F(1,18) ¼ 0.105, p ¼ 0.750).
TAB L E 1 Study 1: Means and SE for
each outcome measure at baseline and
each measurement point postdose
Baseline Prestress Poststress
Mean SE Mean SE Mean SE
Perceived stress Zembrin® 22.2 2.8 ‐ ‐ ‐ ‐
Placebo 23.3 2.8 ‐ ‐ ‐ ‐
Mental demand Zembrin® ‐ ‐ ‐ ‐ 64.1 4.65
Placebo ‐ ‐ ‐ ‐ 63.7 4.65
Physical demand Zembrin® ‐ ‐ ‐ ‐ 26.8 6.64
Placebo ‐ ‐ ‐ ‐ 22.3 6.64
Temporal demand Zembrin® ‐ ‐ ‐ ‐ 62.7 5.65
Placebo ‐ ‐ ‐ ‐ 49.6 5.65
Effort Zembrin® ‐ ‐ ‐ ‐ 61.5 4.40
Placebo ‐ ‐ ‐ ‐ 64.8 4.40
Performance Zembrin® ‐ ‐ ‐ ‐ 64.4 5.08
Placebo ‐ ‐ ‐ ‐ 63.3 5.08
Frustration Zembrin® ‐ ‐ ‐ ‐ 38.2 6.83
Placebo ‐ ‐ ‐ ‐ 31.3 6.83
Hunger scale Zembrin® 43.5 7.44 ‐ ‐ 58.95 2.48
Placebo 69.5 2.72 ‐ ‐ 59.04 2.30
Word recall (number correct) Zembrin® 8.4 0.41 8.56 0.86 ‐ ‐
Placebo 9.9 0.53 9.91 0.81 ‐ ‐
Word recall (number error) Zembrin® 0.2 0.15 0.41 0.18 ‐ ‐
Placebo 0.5 0.22 0.33 0.17 ‐ ‐
Alert Zembrin® 53.18 4.40 61.67 2.97 66.88 3.29
Placebo 53.84 4.12 61.42 2.97 62.84 3.29
Calm Zembrin® 67.35 4.93 61.6 4.02 47.04 4.95
Placebo 66.4 4.47 61.3 4.01 45.50 4.95
Content Zembrin® 58.5 2.83 60.99 1.23 59.44 1.75
Placebo 58.6 2.91 58.58 1.23 56.07 1.75
Abbreviation: SE, standard error.
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3.2.2 | Stress induction
A trend toward a main effect of time on STAI(s) (F(2,14) ¼ 3.49,
p ¼ 0.059) and HR (F(2,14) ¼ 3.325, p ¼ 0.06) coupled with a main
effect of time on VA(a) (F(3,21) ¼ 3.23, p ¼ 0.043) confirmed stress
induction.
3.2.3 | Effects of treatment
STAI (state): ANCOVA revealed a treatment � time interaction
(F(1,17) ¼ 8.05, p ¼ 0.011). Post hoc analysis revealed a difference at
prestress (p ¼ 0.009, d ¼ 1.01) with anxiety level significantly lower
in the Zembrin® group (Figure 2).
VAa scale: ANCOVA revealed a treatment � time interaction
(F(2,34) ¼ 3.28, p ¼ 0.05). Post hoc analysis revealed a difference at
prestress (p ¼ 0.024, d ¼ 1.11) with anxiety level being significantly
lower in the Zembrin® group (Figure 2).
HR: ANCOVA revealed a treatment � time interaction (F(1,17) ¼
6.08, p ¼ 0.025). The pattern of results demonstrates a physiological
response to the stressor (increased HR) in placebo but not Zembrin®
group (Figure 3).
4 | DISCUSSION
Results of the current studies provide the first tentative behavioral
evidence to support the anxiolytic properties of Sceletium tortuosum
(25 mg Zembrin®) but fail to replicate the previously reported
enhancement of cognitive function. In the current studies, stress
induction was confirmed in study 1 as participants reported
increased subjective experience of alertness and decreased feelings
of calmness following completion of the MTF (see Wetherell &
Carter, 2014) and in study 2 by participants reporting elevated
feelings of anxiety/stress and increased HR following completion of
the simulated public speech task. With regard to the therapeutic
properties of Sceletium tortuosum (Zembrin®), study 1 failed to show
any effect of treatment on feelings stress or memory performance;
however, study 2 demonstrated that Sceletium tortuosum (Zembrin®)
ameliorated the anticipatory increase in subjective feelings of anxiety
associated with the anticipated onset of a stressor and ameliorated
increases in HR during a stressor.
The lack of an anxiolytic effect in study 1 and on subjective
measures at the mid and poststress testing points in study 2 could
most parsimoniously be explained by our protocol. For example,
despite both protocols inducting elevated feelings of stress, it could
be that the stressor was too “mild” to allow a treatment effect to be
observed in those subjective self‐report measures. For example, it is
clear that our participants did not rate their reported anxiety
greater than the half‐way point on the anxiety scale nor score more
than half on the STAI(s). However, it should be noted that an effect
was observed in the physiological measure. With regard to a lack of
effect on cognitive function, we could interpret this result as the
first evidence to suggest that Sceletium tortuosum (Zembrin®) has no
impact on nonexecutive memory processing in healthy volunteers;
however, we would advise some caution with this, as our primary
aim was to investigate the anxiolytic properties and our research
design was tailored toward this question and it is possible that again
our lack of effect here can also be due to differences between our
study and previous studies. For example, Terburg et al. (2013) uti-
lized a longer treatment regime, tested a different population (older
adults), and assessed different cognitive functioning (i.e., executive
functioning). We recommend that future studies consider using
protocols that elicit stronger stress responses, for example, adding
critical social evaluation to the MTF (e.g., Wetherell et al., 2017), or
running a longer, and more challenging social evaluation paradigm
TAB L E 2 Study 2: Means and SE for
each outcome measure at baseline and
each measurement point postdose
Baseline Prestress Midstress Poststress
Mean SE Mean SE Mean SE Mean SE
STAI (trait) Zembrin® 39 2.75 ‐ ‐ ‐ ‐ ‐ ‐
Placebo 40.25 2.25 ‐ ‐ ‐ ‐ ‐ ‐
STAI (state) Zembrin® 30.58 2.06 33.96 2.81 ‐ ‐ 37.82 2.22
Placebo 35.38 2.20 44.43 3.48 ‐ ‐ 35.88 2.75
Anxiety scale Zembrin® 2.25 0.39 3.25 0.48 4.42 0.59 4.25 0.46
Placebo 3.63 0.885 4.61 0.6 4.99 0.74 3.49 0.57
HR (bpm) Zembrin® 87.1 5.19 91.8 2.09 90.5 2.27 ‐ ‐
Placebo 87.52 5.63 87.09 2.57 93.85 2.78 ‐ ‐
GSR Zembrin® 0.74 0.007 0.73 0.002 0.71 0.002 ‐ ‐
Placebo 0.71 0.88 0.75 0.002 0.74 0.002 ‐ ‐
Note: HR and GSR is average data at baseline (5 min), prestress (30 min), and midstress (5 min).
Abbreviations: GSR, galvanic skin response; HR, heart rate; SE, standard error; STAI, State–Trait
Anxiety Inventory.
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to further our understanding of the anxiolytic effects of Sceletium
tortuosum (Zembrin®). Future studies should also use more
comprehensive cognitive assessment to investigate whether Scele-
tium tortuosum (Zembrin®) has any task/cognitive domain specificity
of effect.
We conclude that a single 25 mg dose of Sceletium tortuosum
(Zembrin®) can ameliorate subjective and physiological indicators of
stress/anxiety during a controlled laboratory stress protocol in young
healthy volunteers.
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